Malaria: Difference between revisions
From WikiDemocracy
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 219: | Line 219: | ||
[https://pmc.ncbi.nlm.nih.gov/articles/PMC6054918/ by Simon J Draper Simon J Draper 11/7/18 NIH] | [https://pmc.ncbi.nlm.nih.gov/articles/PMC6054918/ by Simon J Draper Simon J Draper 11/7/18 NIH] | ||
The development of highly effective and durable vaccines against the human malaria parasites Plasmodium falciparum and P. vivax remains a key priority. Decades of endeavor have taught that achieving this goal will be challenging; however, recent innovation in malaria vaccine research and a diverse pipeline of novel vaccine candidates for clinical assessment provides optimism. | The development of highly effective and durable vaccines against the human malaria parasites Plasmodium falciparum and P. vivax remains a key priority. Decades of endeavor have taught that achieving this goal will be challenging; however, recent innovation in malaria vaccine research and a diverse pipeline of novel vaccine candidates for clinical assessment provides optimism. | ||
=====Malaria Vaccines: Recent Advances and New Horizons===== | |||
[https://pmc.ncbi.nlm.nih.gov/articles/PMC6054918/ by Simon J Draper NIH] | |||
The development of highly effective and durable vaccines against the human malaria parasites Plasmodium falciparum and P. vivax remains a key priority. Decades of endeavor have taught that achieving this goal will be challenging; however, recent innovation in malaria vaccine research and a diverse pipeline of novel vaccine candidates for clinical assessment provides optimism. With first-generation pre-erythrocytic vaccines aiming for licensure in the coming years, it is important to reflect on how next-generation approaches can improve on their success. | |||
